 EDISON, N.J., March 23, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, Hepion, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease DIAMOND.1 